Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors
Phase 1 Completed
96 enrolled
Trial of PTK787/ZK 222584 Plus Paclitaxel
Phase 1 Terminated
7 enrolled
PTK/ZK in Disseminated Malignant Melanoma
Phase 1/2 Terminated
9 enrolled
Study of Oxaliplatin/5-FU/Leucovorin Plus Vatalanib Versus Oxaliplatin/5-FU/Leucovorin in Patients With Metastatic Colorectal Cancer.
Phase 3 Completed
1,168 enrolled
Vatalanib and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors
Phase 1 Completed
29 enrolled
Vatalanib in Treating Patients With Recurrent or Progressive Meningioma
Phase 2 Completed
25 enrolled 10 charts
Docetaxel and PTK787 in Metastatic Breast Cancer Patients and Gynecological Cancer Patients
Phase 1 Completed
24 enrolled
Treatment of Von Hippel-Lindau (VHL)-Related Hemangioblastoma With PTK787/ZK 222584
Phase 2 Completed
11 enrolled
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
Phase 2 Completed
155 enrolled 10 charts
PTK787/ZK 222584 in Treating Patients With Unresectable Malignant Mesothelioma
Phase 2 Completed
47 enrolled
PTK/RAD
Phase 1 Completed
37 enrolled
PTK787 + Trastuzumab for HER2 Overexpressing Metastatic Breast Cancer
Phase 1/2 Terminated
7 enrolled
Imatinib Mesylate, Vatalanib, and Hydroxyurea in Treating Patients With Recurrent or Relapsed Malignant Glioma
Phase 1 Completed
37 enrolled
Vatalanib and Octreotide in Treating Patients With Progressive Neuroendocrine Tumors
Phase 2 Withdrawn
Study of PTK787 in the Treatment of Patients With Non-Metastatic Androgen Independent Prostate Cancer
Phase 2 Completed
5 enrolled
Safety and Efficacy Study of a New Chemotherapy Agent to Treat Non Small Cell Lung Cancer.
Phase 2 Completed
112 enrolled
PTK787 in Refractory or Relapsed Diffuse Large Cell Lymphoma
Phase 2 Terminated
20 enrolled
PTK/ZK as Post Transplant Maintenance Therapy in Patients With Multiple Myeloma
Phase 2 Terminated
21 enrolled 11 charts
Phase 1-2 Vatalanib and Gemcitabine in Advanced Pancreatic Cancer
Phase 1/2 Completed
33 enrolled 10 charts
Phase I, Pharmacokinetic, Pharmacodynamic Trial of PTK787 and Paclitaxel in Combination for Advanced Solid Tumors
Phase 1 Completed
28 enrolled
PTK787/ZK 222584 in Combination With Temozolomide and Radiation in Patients With Glioblastoma Taking Enzyme-Inducing Anti-Epileptic Drugs
Phase 1 Completed
19 enrolled
Vatalanib in Treating Patients With Metastatic Cutaneous Melanoma That Cannot be Removed by Surgery
Phase 2 Completed
34 enrolled
PTK and Letrozole in Post-menopausal Women With Advanced Breast Cancer
Phase 2 Terminated
4 enrolled
Docetaxel, Prednisone, and Vatalanib in Treating Patients With Advanced Prostate Cancer
Phase 1/2 Terminated
6 enrolled
Temozolomide and Radiation Therapy With or Without Vatalanib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Phase 1/2 Completed
20 enrolled
PTK787 in Patients With Advanced Metastatic Pancreatic Adenocarcinoma
Phase 2 Completed
67 enrolled
Phase I/II Trial of PTK787 and Pemetrexed With or Without Cisplatin for Lung Cancer
Phase 1/2 Terminated
20 enrolled
PTK 787 and Gleevec in Patients With AML, AMM, and CML-BP
Phase 1/2 Completed
9 enrolled
PTK787
Phase 2 Completed
23 enrolled
PTK787/ZK222584 in the Treatment of Metastatic Gastrointestinal Stromal Tumors Resistant to Imatinib
Phase 2 Completed
45 enrolled
Study of the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Effects of Vatalanib in Combination With Capecitabine in Patients With Advanced Cancer
Phase 1/2 Completed
22 enrolled
PTK787/ZK222584 With Bevacizumab in Patients With Refractory and/or Advanced Malignancies
Phase 1 Completed
50 enrolled
Protein Tyrosine Kinases (PTK) in Multiple Myeloma
Phase 2 Completed
10 enrolled